Loading
A phase 2 trial of Acalabrutinib in waldenström macroglobulinaemia, run by Acerta Pharma BV, active and no longer recruiting.
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia is a phase 2 interventional study registered as NCT02180724 by Acerta Pharma BV, with 107 participants enrolled, started 2014-09-11 and due to reach its primary completion in 2019-10-01. Interventions recorded: Acalabrutinib (ACP-196). Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
107 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2020-04-24), not from a publication
SourceFigures from the ClinicalTrials.gov results section (first posted 2020-04-24), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 6th Criteria, ORR 6th IWWM criteria (CR+VGPR+PR+MR)primary | Previously Treated (N=92) | 92 | 87 participants | - | - | link |
| Treatment Naive (N=14) | 14 | 13 participants | ||||
| Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 3rd Criteria, ORR 3rd IWWM criteria (CR+VGPR+PR+MR)primary | Previously Treated (N=92) | 92 | 87 participants | - | - | link |
| Treatment Naive (N=14) | 14 | 13 participants |
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.